RADNOR, Pa.--(BUSINESS WIRE)--
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that members of its leadership team will present at the following investor conferences in November and December.
12th Annual Jefferies London Healthcare Conference
-
Date and Time: Available on demand starting Thursday, November 18, 3:00 a.m. ET through Friday, November 19, 12:00 p.m. ET
-
Speakers: Scott Braunstein, M.D., Chief Executive Officer and Steven Pfanstiel, Chief Financial Officer
-
Webcast Link:
https://wsw.com/webcast/jeff201/mrns/1865664
Marinus Pharmaceuticals Virtual Investor Event at American Epilepsy Society 2021 Annual Meeting
Jefferies Denver Healthcare Summit
-
Date and Time: Thursday, December 16
-
One-on-one meetings with Marinus leadership open only to Jefferies conference participants
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder last year, is planning to conduct a Phase 3 trial in tuberous sclerosis complex, and a Phase 3 trial in refractory status epilepticus is ongoing. For more information visit www.marinuspharma.com.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20211115005040/en/
Sasha Damouni Ellis
Vice President, Corporate Affairs & Investor Relations
Marinus Pharmaceuticals, Inc.
484-253-6792
sdamouni@marinuspharma.com
Source: Marinus Pharmaceuticals